Hess G, Manns M, Hütteroth T H, Meyer zum Büschenfelde K H
Digestion. 1987;36(1):47-54. doi: 10.1159/000199398.
Immunosuppressive therapy was stopped in 12 individuals positive for hepatitis Be antigen (HBeAg) and hepatitis B surface antigen (HBsAg) and in 4 individuals positive for HBsAg but negative for HBeAg. Discontinuation of immunosuppressive therapy in HBeAg-positive patients was always associated with a bout of hepatitis and elimination of HBeAg in 8/12 patients. One patient died from liver failure and 2 patients experienced a decompensation of their liver disease indicating that this approach might be harmful if used therapeutically. A bout of hepatitis was not noted in any of the individuals negative for HBeAg when the immunosuppressive therapy was stopped, implying that this event is not potentially harmful to the patient.
对12例乙肝e抗原（HBeAg）和乙肝表面抗原（HBsAg）均呈阳性的患者以及4例HBsAg呈阳性但HBeAg呈阴性的患者停止了免疫抑制治疗。在HBeAg阳性患者中停止免疫抑制治疗总是伴随着一阵肝炎发作，并且12例患者中有8例HBeAg消失。1例患者死于肝衰竭，2例患者出现肝病失代偿，这表明如果将这种方法用于治疗可能是有害的。当停止免疫抑制治疗时，在任何HBeAg呈阴性的个体中均未发现一阵肝炎发作，这意味着该事件对患者没有潜在危害。
